Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

PRIMARY OBJECTIVES: I. Assess the activity of bevacizumab, in terms of 6-month progression-free survival rate and objective tumor response, in patients with recurrent or persistent endometrial cancer. II. Determine the nature and degree of toxicity of bevacizumab in these patients. SECONDARY OBJECTIVES: I. Determine the duration of progression-free survival and overall survival of these patients. II. Determine the effects of prognostic factors, including performance status and histological grade. OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically.